Strides Pharma Science Limited
Valuation (92/100) does the heavy lifting; momentum (48/100) is the drag.
Buy zoneOur blended model reads Strides Pharma Science Limited as a Buy at 71/100. At ₹1,025 it trades below our blended DCF and relative-multiples fair value of ₹2,050, about 100% upside to that estimate — we read it as undervalued by 100%. On 16.9x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 13% below its 52-week high of ₹1,182.56 and 30% above the low of ₹789.85. Financial health scores 38/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹1,338.67 implies about 31% upside across 3 analysts. It clears 7 of 13 investability checks, with durability 60, valuation 84 and momentum 48 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,640. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-13.32% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy71Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 20.0%
- Fail: Low debt (D/E < 0.5): 0.56x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 11%
- Pass: Earnings growing: 54%
- Pass: Net margin ≥ 10%: 11.4%
- Fail: Current ratio > 1.5: 1.25
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.52
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter30.8%
- Institutions29.1%
- Public & other40.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (20.0%).
Opportunities
- Earnings growing (54% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~100% below our estimated fair value.
About Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous
Strides Pharma Science Limited — frequently asked questions
Is Strides Pharma Science Limited a buy, hold or sell?
StocksWizard currently rates Strides Pharma Science Limited (STAR) a Buy, based on a blended score of 71/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Strides Pharma Science Limited's fair value?
Our blended DCF and relative-valuation model estimates Strides Pharma Science Limited's fair value at about ₹2,050, versus a current price of ₹1,025 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
Is Strides Pharma Science Limited financially healthy?
Strides Pharma Science Limited scores 38/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Strides Pharma Science Limited's share price performed?
Strides Pharma Science Limited is down 2% over three months, and last traded at ₹1,025. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.